Quoin Pharmaceuticals (QNRX) Price & Analysis

Compare

332 Followers

QNRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.01 - $54.95

Previous CloseN/A

Volume155.80K

Average Volume (3M)4.07K

Market Cap

$4.34M

Enterprise Value-$7.64M

Total Cash (Recent Filing)$1.67M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.28

Next Earnings

Nov 06, 2025

EPS Estimate

-5.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.28

Shares Outstanding588,167

10 Day Avg. Volume3,443

30 Day Avg. Volume4,071

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.76

Enterprise Value/Revenue-76.07

Enterprise Value/Gross Profit302.04

Enterprise Value/Ebitda0.61

Forecast

1Y Price Target

$70.00

Price Target Upside848.51% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical DataConsistent positive data from QRX003 trials, including skin clearing and symptom reduction, supports its potential efficacy and safe tolerability in treating Netherton Syndrome.

Market PotentialQRX003's potential approval could provide Quoin Pharmaceuticals with a significant market opportunity due to the lack of existing treatments for Netherton Syndrome.

Regulatory ProgressThe FDA has granted QRX003 Rare Pediatric Disease Designation, which can expedite its review process and increase the likelihood of approval.

Bears Say

Chronic Treatment RequirementQRX003 may likely be required as a chronic therapy and does exhibit a clinical effect on patients.

Stock PerformanceThe shares are trading down ~25% as some investors may be concerned that QRX003 did not maintain symptom relief durability or 'cure' patients.

Treatment DurabilityUpdated data showed that 4 weeks post-discontinuation of therapy, the patients’ symptom and disease severity scores returned essentially to baseline levels.

Quoin Pharmaceuticals News

Quoin’s ‘NETHERTON NOW’ campaign surpasses 1M video views

Quoin Pharmaceuticals (QNRX) announced that its NETHERTON NOW awareness campaign has surpassed a major milestone, achieving more than...

8d ago

QNRX

Quoin Pharmaceuticals appoints Lawlor as Chief Financial Officer

Quoin Pharmaceuticals (QNRX) announced the appointment of its new Chief Financial Officer as the Company advances its lead...

11d ago

QNRX

Quoin Pharmaceuticals releases fourth episode of NETHERTON NOW series

Quoin Pharmaceuticals (QNRX) announced the release of the fourth episode in its NETHERTON NOW video series. This installment...

17d ago

QNRX

Quoin Pharmaceuticals reports Q2 EPS ($6.28) vs ($13.68) last year

“Second quarter of 2025 was one of the most impactful in Quoin’s history, marked by meaningful progress on...

22d ago

QNRX

Quoin Pharmaceuticals Announces CFO Departure Agreement

Quoin Pharmaceuticals ( ($QNRX) ) has shared an update. Quoin Pharmaceuticals Ltd. announced the mutual separation with its...

2d ago

QNRX

Quoin Pharmaceuticals Appoints New CFO Sally Lawlor

Quoin Pharmaceuticals ( ($QNRX) ) just unveiled an announcement. At the 2025 Annual Meeting, Quoin Pharmaceuticals‘ shareholders approved...

8d ago

QNRX

Quoin Pharmaceuticals Reports Q2 2025 Financial Results

Quoin Pharmaceuticals Ltd ( ($QNRX) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

QNRX

Buy Rating for Quoin Pharmaceuticals: Promising Developments in Netherton Syndrome Treatment and Strategic Regulatory Advantages

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals, with a price target of...

29d ago

QNRX

Quoin Pharmaceuticals provides update on its development product portfolio

Quoin Pharmaceuticals (QNRX) provided an updated overview of its development product portfolio. The company’s lead product, QRX003 for...

1M ago

QNRX

Quoin Pharmaceuticals CFO Departure Announcement

Quoin Pharmaceuticals ( ($QNRX) ) just unveiled an announcement. On July 3, 2025, Quoin Pharmaceuticals Ltd. announced that...

2M ago

QNRX

Quoin Pharmaceuticals releases new ‘NETHERTON NOW’ video

Quoin Pharmaceuticals (QNRX) announced the release of a new episode in its NETHERTON NOW video series. The episode...

2M ago

QNRX

Quoin Pharmaceuticals Receives FDA Rare Disease Designation

Quoin Pharmaceuticals ( ($QNRX) ) has shared an update. On June 24, 2025, Quoin Pharmaceuticals announced that the...

2M ago

QNRX

Quoin Pharmaceuticals announces FDA granted RPD designation for QRX003

Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration, FDA, has granted Rare Pediatric Disease, RPD,...

2M ago

QNRX

Quoin Pharmaceuticals Updates Shareholder Proposal Deadlines

The latest update is out from Quoin Pharmaceuticals ( ($QNRX) ). Quoin Pharmaceuticals Ltd. has announced that its...

2M ago

QNRX

QNRX FAQ

What was Quoin Pharmaceuticals’s price range in the past 12 months?

Quoin Pharmaceuticals lowest stock price was $5.01 and its highest was $54.95 in the past 12 months.

What is Quoin Pharmaceuticals’s market cap?

Quoin Pharmaceuticals’s market cap is $4.34M.

When is Quoin Pharmaceuticals’s upcoming earnings report date?

Quoin Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.

How were Quoin Pharmaceuticals’s earnings last quarter?

Quoin Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$6.28 earnings per share for the quarter, beating the consensus estimate of -$6.82 by $0.54.

Is Quoin Pharmaceuticals overvalued?

According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Quoin Pharmaceuticals pay dividends?

Quoin Pharmaceuticals does not currently pay dividends.

What is Quoin Pharmaceuticals’s EPS estimate?

Quoin Pharmaceuticals’s EPS estimate is -5.17.

How many shares outstanding does Quoin Pharmaceuticals have?

Quoin Pharmaceuticals has 588,167 shares outstanding.

What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?

Quoin Pharmaceuticals reported an EPS of -$6.28 in its last earnings report, beating expectations of -$6.82. Following the earnings report the stock price went down -6.242%.

Which hedge fund is a major shareholder of Quoin Pharmaceuticals?

Currently, no hedge funds are holding shares in QNRX

Company Description

Quoin Pharmaceuticals

Quoin Pharmaceuticals (QNRX) is a biopharmaceutical company focused on developing and commercializing innovative therapeutic products. The company operates primarily in the pharmaceutical sector, aiming to address unmet medical needs in rare and orphan diseases. Quoin Pharmaceuticals is dedicated to advancing its pipeline of products through rigorous research and development efforts to bring new treatment options to patients around the world.

Quoin Pharmaceuticals (QNRX) Earnings & Revenues

Historic Earnings Reports

QNRX Stock 12 Month Forecast

Average Price Target

$70.00

▲(848.51% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","190":"$190","51.25":"$51.3","97.5":"$97.5","143.75":"$143.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,51.25,97.5,143.75,190],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,11.68,16.54,21.400000000000002,26.26,31.12,35.980000000000004,40.84,45.7,50.56,55.42,60.28,65.14000000000001,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,11.68,16.54,21.400000000000002,26.26,31.12,35.980000000000004,40.84,45.7,50.56,55.42,60.28,65.14000000000001,{"y":70,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,11.68,16.54,21.400000000000002,26.26,31.12,35.980000000000004,40.84,45.7,50.56,55.42,60.28,65.14000000000001,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":189,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.95,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.86,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.54,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.31,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.77,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.87,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.82,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >